848083-91-0

Upstream product

• 848083-89-6 N-[(tert-butoxy)carbonylamino]-6-[(fluoren-9-ylmethoxy)carbonylamino]hexanamide 
• 848083-90-9 BocNHNHCO(CH₂)5NH₂ 
• 911141-44-1 6-({(1E)-2-[2-(sodiooxysulfonyl)phenyl]-1-azavinyl}amino)pyridine-3-carboxylic acid 
• 848083-49-8 2-[[[5-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]-2-pyridinyl]hydrazono]methyl]-benzenesulfonic acid, monosodium salt 

Downstream Products

• 848084-07-1 C₂₁H₂₆N₆O₆S 
• 848084-09-3 C₃₁H₄₆N₆O₆S 
• 848084-08-2 C₃₁H₄₆N₆O₇S 
• 848084-14-0 C₃₃H₄₂N₈O₈S 
• 848083-92-1 2-{(1E)-2-[(5-{N-[5-(N-aminocarbamoyl)pentyl]carbamoyl}(2-pyridyl))amino]-2-azavinyl}benzenesulfonic acid 

Relevant academic research and scientific papers

HYDRAZIDE CONJUGATES AS IMAGING AGENTS

The present disclosure is directed to diagnostic agents. More specifically, the disclosure is directed to compounds, diagnostic agents, compositions, and kits for detecting and/or imaging and/or monitoring a pathological disorder associated with coronary plaque, carotid plaque, aortic plaque, plaque of the arterial vessel, aneurism, vasculitis, and other diseases of the arterial wall. In addition, the disclosure is directed to methods of detecting and/or imaging and/or monitoring changes in the arterial wall, including expansive and constrictive remodeling, total vessel wall area, internal lumen size, and exterior artery perimeter.

COMPOUNDS CONTAINING MATRIX METALLOPROTEINASE SUBSTRATES AND METHODS OF THEIR USE

Compounds for use in a diagnostic agent for detecting, imaging, and/or monitoring a pathological disorder associated with matrix metalloproteinase activity at a site of interest in a patient are disclosed. Compositions and kits containing the compounds are also disclosed. In addition, methods of detecting, imaging, and/or monitoring the presence of matrix metalloproteinase or a pathological disorder associated with matrix metalloproteinase activity in a patient are disclosed.